Menu ausklappen

Publikationen

Aktuelle Publikationen von Prof. Dr. med. H. Bojar

alle Publikationen bei PubMed anzeigen

pubmed-small

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.
Poremba C, Uhlendorff J, Pfitzner BM, Hennig G, Bohmann K, Bojar H, Krenn V, Brase JC, Haufe F, Averdick M, Dietel M, Kronenwett R, Denkert C.

pubmed-small

Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study.
Matuschek C, Lehnhardt M, Gerber PA, Poremba C, Hamilton J, Lammering G, Orth K, Budach W,Bojar H, Bölke E, Peiper M.

pubmed-small

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.
Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S.

pubmed-small

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission : results of a multivariate analysis.
Matuschek C, Bölke E, Roth SL, Orth K, Lang I, Bojar H, Janni JW, Audretsch W, Nestle-Kraemling C, Lammering G, Speer V, Gripp S, Gerber PA, Buhren BA, Sauer R, Peiper M, Schauer M, Dommach M, Struse-Soll K, Budach W.

pubmed-small

A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.
Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG.

pubmed-small

Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients.
Matuschek C, Rudoy M, Peiper M, Gerber PA, Hoff NP, Buhren BA, Flehmig B, Budach W, Knoefel WT, Bojar H, Prisack HB, Steinbach G, Shukla V, Schwarz A, Kammers K, Erhardt A, Scherer A, Bölke E, Schauer M.

pubmed-small

Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy.
Roth SL, Audretsch W, Bojar H, Lang I, Willers R, Budach W.Strahlenther Onkol. 2010 Jun;186(6):299-306. doi: 10.1007/s00066-010-2143-0. Epub 2010 May 21.

pubmed-small

[Nitazoxanide (“Alinia”)–a promising antiparasitic drug].
Bojar H, Knap JP.
Wiad Parazytol. 2010;56(1):11-8. Review. Polish.

pubmed-small

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.
Clin Cancer Res. 2010 Apr 15;16(8):2391-401. doi: 10.1158/1078-0432.CCR-09-2471. Epub 2010 Apr 6.

pubmed-small

Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence.
Winzer KJ, Sauerbrei W, Braun M, Liersch T, Dunst J, Guski H, Schumacher M; German Breast Cancer Study Group (GBSG).
Eur J Cancer. 2010 Jan;46(1):95-101. doi: 10.1016/j.ejca.2009.10.007. Epub .

pubmed-small

Gene expression of circulating tumour cells in breast cancer patients.
Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H.pub .

pubmed-small

Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients.
Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, Matuschek C, Budach W, Rusnak E, Shaikh S, Dogan B, Prisack HB, Bojar H.

pubmed-small

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

pubmed-small

ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis.
Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, Bojar H, Tannapfel A, Hengge UR.

pubmed-small

Can a 70-gene signature provide useful prognostic information in patients with node-negative breast cancer?
Modlich O, Bojar H.
Nat Clin Pract Oncol. 2007 Apr;4(4):216-7. Epub 2007 Feb 6. No abstract available.

pubmed-small

Expression analysis of pancreatic cancer cell lines reveals association of enhanced gene transcription and genomic amplifications at the 8q22.1 and 8q24.22 loci.
Domagk D, Schaefer KL, Eisenacher M, Braun Y, Wai DH, Schleicher C, Diallo-Danebrock R, Bojar H, Roeder G, Gabbert HE, Domschke W, Poremba C.
Oncol Rep. 2007 Feb;17(2):399-407.

pubmed-small

Breast cancer expression profiling: the impact of microarray testing on clinical decision making.
Modlich O, Prisack HB, Bojar H.
Expert Opin Pharmacother. 2006 Oct;7(15):2069-78. Review.

pubmed-small

Gene expression in acute Stanford type A dissection: a comparative microarray study.
Weis-Müller BT, Modlich O, Drobinskaya I, Unay D, Huber R, Bojar H, Schipke JD, Feindt P, Gams E, Müller W, Goecke T, Sandmann W.
J Transl Med. 2006 Jul 6;4:29.

pubmed-small

STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases.
Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, Tannapfel A, Bojar H, Ruzicka T, Hengge UR.
J Invest Dermatol. 2006 Oct;126(10):2272-80. Epub 2006 Jun 1.

pubmed-small

Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.
Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, Bojar H.
Anticancer Res. 2005 Nov-Dec;25(6C):4615-21.

pubmed-small

Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model.
Liebau C, Roesel C, Schmidt S, Karreman C, Prisack JB, Bojar H, Merk H, Wolfram N, Baltzer AW.
Anticancer Res. 2004 Sep-Oct;24(5A):2861-7.

pubmed-small

Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease.
Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H.
Clin Cancer Res. 2004 Oct 1;10(19):6418-31.

pubmed-small

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.
Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO.
Clin Cancer Res. 2004 May 15;10(10):3410-21.

pubmed-small

Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector.
Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl U, Fenk R, Opalka B, Pitschke G, Prisack HB, Bojar H, Haas R, Kronenwett R.
Cancer Gene Ther. 2003 Dec;10(12):898-906.

pubmed-small

Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells.
Liebau C, Merk H, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H, Baltzer AW.
Cytokines Cell Mol Ther. 2002;7(4):135-42.